Imperia Performance Plus
Imperia Performance Plus, licence 80044874: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- Imperia Wyfe
- Licence holder
- Imperia Brand Strategies & Solutions Ltd.
- NPN or DIN-HM
- 80044874
- Status
- Active licence
- Licence date
- 23 September 2013
- Revision date
- Not provided
- Form
- Gel
- Route of administration
- Topique
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Acide 4-aminobenzoïque, Ester d'éthyle Source : Acide para-aminobenzoïque | 7.5 % | Not calculated |
Non-medicinal ingredients
Carbomère, PEG-400
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19.0 Année(s) | Not specified | Not specified |
Uses authorised in Canada
For reducing oversensitivity in advance of intercourse. For temporary male genital desensitisation, helping to slow the onset of ejaculation. Helps in temporarily retarding the onset of ejaculation/temporarily slowing the onset of ejaculation/temporarily prolonging the time until ejaculation. Helps in the prevention of premature ejaculation.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
Hypersensitivity/allergy has been known to occur; in which case, discontinue use.
- Précautions et mises en garde
Premature ejaculation may be due to a condition requiring medical supervision. If this product, used as directed, does not provide relief, discontinue use and consult a health care practitioner.
- Contre-indications
If the following symptoms appear: weakness, confusion, headache, difficulty breathing and/or pale, gray or blue coloured skin, stop use and consult a health care practitioner. These symptoms may be signs of methemoglobinemia, a rare disorder, which may appear up to 2 hours after use.
Source
Official Health Canada record, licence 80044874
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.